



Entacapone

Catalog No: tcsc1266

| F | 7 |
|----|---|
| ٠, | 7 |
| 4 | |

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

130929-57-6

Formula:

 $C_{14}^{}H_{15}^{}N_{3}^{}O_{5}^{}$

Pathway:

Neuronal Signaling; Metabolic Enzyme/Protease

Target:

COMT;COMT

Purity / Grade:

>98%

Solubility:

DMSO: 33.33 mg/mL (109.17 mM; Need ultrasonic)

Observed Molecular Weight:

305.29

Product Description

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.





IC50 Value: 151 nM

Target: COMT

in vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (

in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson\'s disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control.

Clinical trial: The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!